Anne Hulin

Dr. Anne Hulin

APHP, HU Henri MONDOR,
+1
orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2017 in Journal of Pharmaceutical and Biomedical Analysis
Verified
Journal Article
Closed access
MAMarie Allard
Marie Allard
NKNihel Khoudour
Nihel Khoudour
BRBenoit Rousseau
Benoit Rousseau
CJCharlotte Joly
Charlotte Joly
CCCharlotte Costentin
Charlotte Costentin
AHAnne Hulin
Anne Hulin

9 May 2015 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
MRMarie Georgine Rakotoson
Marie Georgine Rakotoson
GLGaetana Di Liberto
Gaetana Di Liberto
EAEtienne Audureau
Etienne Audureau
AHAnoosha Habibi
Anoosha Habibi
CFChristine Fauroux
Christine Fauroux
PBPablo Bartolucci
Pablo Bartolucci
Dense red blood cells (DRBCs) are associated with chronic clinical manifestations of sickle-cell–disease (SCD). Hydroxyurea (HU) decreases the percent (%) DRBCs, thereby improving its therapeutic benefits, especially the prevention of SCD clinical complications, but parameters influencing %DRBCs remain unknown. The purpose of this study was to determine predictive biological parameters of %DRBC decline under HU. Factors affecting the %DRBC decrease in SCD patients HU-treated for ≥6 months were analyzed. Biological parameters and the %DRBCs were determined before starting HU and after ≥6 months of HU intake. Bivariate analyses evaluated the impact of each biological parameter variation on %DRBC changes under treatment. Multivariate analyses assessed the correlations between the decreased %DRBCs and biological parameters. The %DRBCs declined by 40.95% after ≥6 months on HU. That decrease was associated with less hemolysis, however in several analyses on this group of patients we did not find a statistically significant correlation between decrease in %DRBCs and increase in HbF. Initial %DRBC values were the most relevant parameter to predict %DRBC decline. Our results strengthen the known HU efficacy in SCD management statistically independently of the classical HbF biological response. Decreasing %DRBCs is essential to limiting chronic SCD symptoms related to DRBCs and predictive factors might help prevent those manifestations. The results of this study provide new perspectives on indication for HU use, i.e., to prevent SCD-induced organ damage.

27 April 2022 in European Journal of Cancer
Verified
Journal Article
Closed access
BRBenoit Rousseau
Benoit Rousseau
ABArezki K. Boukerma
Arezki K. Boukerma
JHJulie Henriques
Julie Henriques
RCRomain Cohen
Romain Cohen
OLOlivier Lucidarme
Olivier Lucidarme
AHAnne Hulin
Anne Hulin

11 December 2023 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
AHAnne Hulin
Anne Hulin
TGThibaut Gelé
Thibaut Gelé
CFCharlotte Fenioux
Charlotte Fenioux
EKEmmanuelle Kempf
Emmanuelle Kempf
DSDil Sahali
Dil Sahali
Mario OlleroMario Ollero
Mario Ollero
Tyrosine kinase inhibitors (TKI) have introduced a significant advancement in cancer management. These compounds are administered orally, and their absorption holds a pivotal role in determining their variable efficacy. They exhibit extensive distribution within the body, binding strongly to both plasma and tissue proteins. Often reliant on efflux and influx transporters, TKI undergo primary metabolism by intestinal and hepatic cytochrome P450 enzymes, with nonkidney clearance being predominant. Owing to their limited therapeutic window, many TKI display considerable intraindividual and interindividual variability. This review offers a comprehensive analysis of the clinical pharmacokinetics of TKI, detailing their interactions with drug transporters and metabolic enzymes, while discussing potential clinical implications. The prevalence of kidney conditions, such as AKI and CKD, among patients with cancer is explored in their effect on TKI pharmacokinetics. Finally, the potential nephrotoxicity associated with TKI is also examined.

20 November 2020 in British Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
CPClaire Pressiat
Claire Pressiat
MRMarie‐Georgine Rakotoson
Marie‐Georgine Rakotoson
AHAnoosha Habibi
Anoosha Habibi
CBCaroline Barau
Caroline Barau
RARaphaele Arrouasse
Raphaele Arrouasse
PBPablo Bartolucci
Pablo Bartolucci

1 December 2023 in Radiology
Verified
Journal Article
Closed access
TSThomas Stehlé
Thomas Stehlé
FWFélix Wei
Félix Wei
SBSéverine Brabant
Séverine Brabant
ALAlain Luciani
Alain Luciani
PGPhilippe Grimbert
Philippe Grimbert
FPFrédéric Pigneur
Frédéric Pigneur
Background Estimating glomerular filtration rate (GFR) from serum creatinine can be inaccurate, and current procedures for measuring GFR are time-consuming and cumbersome. Purpose To develop a method for measuring GFR based on iomeprol clearance assessed at CT urography in kidney donor candidates and compare this with iohexol clearance (reference standard for measuring GFR). Materials and Methods This cross-sectional retrospective study included data from kidney donor candidates who underwent both iohexol clearance and CT urography between July 2016 and October 2022. CT-measured GFR was calculated as the iomeprol excretion rate in the urinary system between arterial and excretory phases (Hounsfield units times milliliters per minute) divided by a surrogate for serum iomeprol concentration in the aorta at the midpoint (in Hounsfield units). Performance of CT-measured GFR was assessed with use of mean bias (mean difference between CT-measured GFR and iohexol clearance), precision (the distance between quartile 1 and quartile 3 of the bias [quartile 3 minus quartile 1], with a small value indicating high precision), and accuracy (percentage of CT-measured GFR values falling within 10%, 20%, and 30% of iohexol clearance values). Intraobserver agreement was assessed for 30 randomly selected individuals with the Lin concordance correlation coefficient. Results A total of 75 kidney donor candidates were included (mean age, 51 years ± 13 [SD]; 45 female). The CT-measured GFR was unbiased (1.1 mL/min/1.73 m2 [95% CI: -1.9, 4.1]) and highly precise (16.2 mL/min/1.73 m2 [quartiles 1 to 3, -6.6 to 9.6]). The accuracy of CT-measured GFR within 10%, 20%, and 30% was 61.3% (95% CI: 50.3, 72.4), 88.0% (95% CI: 80.7, 95.4), and 100%, respectively. Concordance between CT-based GFR measurements taken 2 months apart was almost perfect (correlation coefficient, 0.99 [95% CI: 0.98, 0.99]). Conclusion In living kidney donors, GFR measured based on iomeprol clearance assessed at CT urography showed good agreement with GFR measured based on iohexol clearance. © RSNA, 2023 Supplemental material is available for this article. See also the editorial by Davenport in this issue.